$LNTH
Lantheus Holdings, Inc.

2016 Form 10-K Financial Statement

#000119312517053986 Filed on February 23, 2017

View on sec.gov

Income Statement

Concept 2016 2015 Q4 2015 Q3
Revenue $301.9M $71.20M $74.12M
YoY Change 2.86% -7.49% -2.06%
Cost Of Revenue $164.1M $37.82M $40.42M
YoY Change 3.88% -14.45% -8.23%
Gross Profit $137.8M $33.38M $33.71M
YoY Change 1.67% 1.89% 6.53%
Gross Profit Margin 45.64% 46.88% 45.47%
Selling, General & Admin $75.37M $17.93M $17.84M
YoY Change -4.15% 9.87% -7.89%
% of Gross Profit 54.71% 53.71% 52.93%
Research & Development $12.20M $3.070M $2.458M
YoY Change -15.01% -34.96% -19.38%
% of Gross Profit 8.86% 9.2% 7.29%
Depreciation & Amortization $800.0K $3.000M $1.900M
YoY Change -93.22% -12.79% -13.64%
% of Gross Profit 0.58% 8.99% 5.64%
Operating Expenses $87.58M $20.99M $20.30M
YoY Change -5.82% -0.19% -9.46%
Operating Profit $56.59M $12.39M $13.41M
YoY Change 33.05% 5.63% 45.41%
Interest Expense $26.62M -$7.860M $7.100M
YoY Change -31.25% -25.36% -167.62%
% of Operating Profit 47.04% -63.43% 52.95%
Other Income/Expense, Net $220.0K $440.0K -$183.0K
YoY Change -438.46% -25.42% -141.5%
Pretax Income $28.29M $4.970M $6.125M
YoY Change -340.23% 176.11% -763.6%
Income Tax $1.532M $1.060M $739.0K
% Of Pretax Income 5.41% 21.33% 12.07%
Net Earnings $26.80M $3.916M $5.386M
YoY Change -282.31% 1625.11% -721.22%
Net Earnings / Revenue 8.88% 5.5% 7.27%
Basic Earnings Per Share $0.84 $0.13 $0.18
Diluted Earnings Per Share $0.82 $0.13 $0.18
COMMON SHARES
Basic Shares Outstanding 32.04M shares 31.47M shares 30.36M shares
Diluted Shares Outstanding 32.66M shares 30.76M shares

Balance Sheet

Concept 2016 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.20M $28.60M $21.90M
YoY Change 79.02% 45.18% -19.19%
Cash & Equivalents $51.20M $28.60M $21.92M
Short-Term Investments
Other Short-Term Assets $5.200M $3.851M $5.210M
YoY Change -38.82% -11.96% 24.05%
Inventory $17.60M $15.62M $16.58M
Prepaid Expenses
Receivables $36.80M $37.29M $39.72M
Other Receivables $0.00 $1.000M $0.00
Total Short-Term Assets $110.8M $90.01M $83.44M
YoY Change 23.11% 10.8% -6.67%
LONG-TERM ASSETS
Property, Plant & Equipment $94.20M $95.65M $92.39M
YoY Change 8.9% -0.37% -3.86%
Goodwill $15.71M $15.71M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.10M $20.51M $20.12M
YoY Change -1.95% -0.34% -27.63%
Total Long-Term Assets $145.1M $152.4M $152.7M
YoY Change -4.79% -5.89% -10.49%
TOTAL ASSETS
Total Short-Term Assets $110.8M $90.01M $83.44M
Total Long-Term Assets $145.1M $152.4M $152.7M
Total Assets $255.9M $242.4M $236.1M
YoY Change 5.57% -0.32% -9.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.90M $11.66M $10.70M
YoY Change 61.54% -25.59% -30.52%
Accrued Expenses $21.20M $18.50M $20.00M
YoY Change 14.59% -25.7% -43.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $3.700M $3.650M $3.650M
YoY Change 0.0%
Total Short-Term Liabilities $43.80M $35.52M $34.32M
YoY Change 23.38% -26.8% -42.42%
LONG-TERM LIABILITIES
Long-Term Debt $274.5M $349.9M $350.4M
YoY Change -21.55% -10.95% -12.23%
Other Long-Term Liabilities $44.10M $34.14M $33.52M
YoY Change 4.26% 1.62% -16.21%
Total Long-Term Liabilities $318.6M $384.0M $383.9M
YoY Change -18.77% -9.96% -12.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.80M $35.52M $34.32M
Total Long-Term Liabilities $318.6M $384.0M $383.9M
Total Liabilities $362.4M $427.7M $426.3M
YoY Change -15.27% -11.35% -14.54%
SHAREHOLDERS EQUITY
Retained Earnings -$359.2M -$363.1M
YoY Change 4.28%
Common Stock $175.9M $175.4M
YoY Change 64.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 0.000 shares
Shareholders Equity -$106.5M -$185.3M -$190.1M
YoY Change
Total Liabilities & Shareholders Equity $255.9M $242.4M $236.1M
YoY Change 5.57% -0.32% -9.18%

Cashflow Statement

Concept 2016 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income $26.80M $3.916M $5.386M
YoY Change -282.31% 1625.11% -721.22%
Depreciation, Depletion And Amortization $800.0K $3.000M $1.900M
YoY Change -93.22% -12.79% -13.64%
Cash From Operating Activities $49.64M $12.62M $5.420M
YoY Change 128.11% -425.26% -73.59%
INVESTING ACTIVITIES
Capital Expenditures -$7.400M -$4.730M -$2.310M
YoY Change -43.73% 66.55% 26.92%
Acquisitions
YoY Change
Other Investing Activities $10.68M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $3.281M -$4.730M -$2.310M
YoY Change -124.95% 67.14% 44.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.90M
YoY Change -30.79%
Debt Paid & Issued, Net $78.73M
YoY Change 4043.63%
Cash From Financing Activities -$30.22M -1.040M -3.020M
YoY Change -3124.72% 188.89% -58.8%
NET CHANGE
Cash From Operating Activities $49.64M 12.62M 5.420M
Cash From Investing Activities $3.281M -4.730M -2.310M
Cash From Financing Activities -$30.22M -1.040M -3.020M
Net Change In Cash $22.71M 6.850M 90.00K
YoY Change 136.27% -196.89% -99.22%
FREE CASH FLOW
Cash From Operating Activities $49.64M $12.62M $5.420M
Capital Expenditures -$7.400M -$4.730M -$2.310M
Free Cash Flow $57.04M $17.35M $7.730M
YoY Change 63.39% -1768.27% -65.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36840138 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
49100000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
151339000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18578000
CY2013Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
6385000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-235517000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14002000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
152138000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19739000
CY2014Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
7435000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-239270000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12144000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10525000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
157057000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
399000
CY2015Q4 us-gaap Deferred Income Taxes And Other Tax Liabilities Noncurrent
DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
32900000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
75990000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30364501 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30364501 shares
CY2015Q4 us-gaap Assets
Assets
242379000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4957000
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
168000
CY2015Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
33800000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
90006000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
154252000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
4558000
CY2015Q4 us-gaap Deferred Tax Liabilities Gross Noncurrent
DeferredTaxLiabilitiesGrossNoncurrent
247000
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
11112000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
175553000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28596000
CY2015Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
8145000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37293000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
303000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
16392000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11657000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1493000
CY2015Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
18502000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1985000
CY2015Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
4644000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
159377000
CY2015Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
415000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72416000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7506000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
349858000
CY2015Q4 us-gaap Noncurrent Assets
NoncurrentAssets
95654000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
136561000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3650000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3851000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Inventory Net
InventoryNet
15622000
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000
CY2015Q4 us-gaap Liabilities
Liabilities
427668000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242379000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20496000
CY2015Q4 us-gaap Goodwill
Goodwill
15714000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34141000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35524000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1437000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5709000
CY2015Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1715000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20509000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
11700000
CY2015Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2407000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
95654000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
171644000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
2301000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.95
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-185289000
CY2015Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
14172000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
2200000
CY2015Q4 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
400000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11450000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359160000
CY2015Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
19900000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1180973 shares
CY2015Q4 lnth Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
20553000
CY2015Q4 lnth Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
22431000
CY2015Q4 lnth Accrued Freight Costs Current
AccruedFreightCostsCurrent
2962000
CY2015Q4 lnth Inventory Raw Materials Noncurrent
InventoryRawMaterialsNoncurrent
1200000
CY2015Q4 lnth Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
2085000
CY2015Q4 lnth Tax Indemnification Receivable
TaxIndemnificationReceivable
17600000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12312000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
155246000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
287000
CY2016Q4 us-gaap Deferred Income Taxes And Other Tax Liabilities Noncurrent
DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
33200000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
82504000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36756106 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36756106 shares
CY2016Q4 us-gaap Assets
Assets
255898000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3685000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1803000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2645000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
65000
CY2016Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
34400000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
110819000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
140915000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3398000
CY2016Q4 us-gaap Deferred Tax Liabilities Gross Noncurrent
DeferredTaxLiabilitiesGrossNoncurrent
0
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
11420000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226462000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51178000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
367000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10906000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1701000
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
21249000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-947000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2109000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1568000
CY2016Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
9370000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36818000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18940000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
4453000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1310000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4017000
CY2016Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
647000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1944000
CY2016Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
144665000
CY2016Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
65000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
80808000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9658000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11975000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
274460000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
235000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
257000
CY2016Q4 us-gaap Noncurrent Assets
NoncurrentAssets
94187000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
140128000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3650000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5183000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4835000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0
CY2016Q4 us-gaap Inventory Net
InventoryNet
17640000
CY2016Q4 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
4000000
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
700000
CY2016Q4 us-gaap Liabilities
Liabilities
362414000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
255898000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15118000
CY2016Q4 us-gaap Goodwill
Goodwill
15714000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34745000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43839000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20060000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3339000
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
10400000
CY2016Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3965000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1915000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3892000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94187000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
176691000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.39
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-106516000
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
14138000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
492000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
300000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.63
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
2100000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
851451 shares
CY2016Q4 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
400000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10441000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332398000
CY2016Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
21900000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1880000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4555277 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1625000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1012606 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.58
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1037337 shares
CY2016Q4 lnth Number Of Commercial Products
NumberOfCommercialProducts
9 Item
CY2016Q4 lnth Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
8040000
CY2016Q4 lnth Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
18861000
CY2016Q4 lnth Accrued Freight Costs Current
AccruedFreightCostsCurrent
2995000
CY2016Q4 lnth Inventory Raw Materials Noncurrent
InventoryRawMaterialsNoncurrent
1200000
CY2016Q4 lnth Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
2297000
CY2016Q4 lnth Asset Retirement Obligation Liabilities Expected Present Value
AssetRetirementObligationLiabilitiesExpectedPresentValue
26900000
CY2016Q4 lnth Tax Indemnification Receivable
TaxIndemnificationReceivable
17900000
CY2016Q4 lnth Consolidated Fixed Charge Coverage Ratio
ConsolidatedFixedChargeCoverageRatio
1 pure
CY2015Q2 lnth Accrued Interest Paid
AccruedInterestPaid
3300000
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
10900000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2140000 shares
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2708000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
2800000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-208000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1402000
CY2014 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
277000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2014 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
773000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1031000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1161000
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
70000
CY2014 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
19024000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2916000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-277000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
325000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37313000
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2014 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
227000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
303000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2366000
CY2014 us-gaap Interest Expense
InterestExpense
42288000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7682000
CY2014 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
-500000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
175000
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
1593000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3563000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1500000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-450000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18251000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4797000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7600000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
176081000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1285000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-279000
CY2014 us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
0
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-207000
CY2014 us-gaap Revenues
Revenues
301600000
CY2014 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
68000
CY2014 us-gaap Interest Paid
InterestPaid
39214000
CY2014 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
228000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-465000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
6000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2014 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
505000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4937000
CY2014 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
CY2014 us-gaap Gross Profit
GrossProfit
125519000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-828000
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
865000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1236000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
958000
CY2014 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2201000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4567000
CY2014 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
61000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4047000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3561000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1500000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2064000
CY2014 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
2392000
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
39417000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2560000
CY2014 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-2719000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2297000
CY2014 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
8137000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
437000
CY2014 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
1065000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
508000
CY2014 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1236000
CY2014 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
317000
CY2014 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
30000
CY2014 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
958000
CY2014 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
817000
CY2014 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
1200000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2366000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1195000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11590000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
215000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
234000
CY2014 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-42288000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2014 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1500000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18080615 shares
CY2014 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
0
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1434000
CY2014 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
19400000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18080615 shares
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
416000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13673000
CY2014 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
35116000
CY2014 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
0
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1031000
CY2014 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
71000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
8000
CY2014 lnth Tax Indemnification Income Loss
TaxIndemnificationIncomeLoss
754000
CY2014 lnth Deferred Tax Assets Valuation Allowance Foreign Currency Translation Adjustments
DeferredTaxAssetsValuationAllowanceForeignCurrencyTranslationAdjustments
159000
CY2014 lnth Operating Expenses Before Gain Loss On Sale Of Assets
OperatingExpensesBeforeGainLossOnSaleOfAssets
86102000
CY2014 lnth Other Comprehensive Income Loss Reclassification Adjustment Due To Sale Of Group Of Assets Liabilities Not Qualifying As Discontinued Operations
OtherComprehensiveIncomeLossReclassificationAdjustmentDueToSaleOfGroupOfAssetsLiabilitiesNotQualifyingAsDiscontinuedOperations
0
CY2014 lnth Income Tax Reconciliation Write Off Of Foreign Tax And Research Credits
IncomeTaxReconciliationWriteOffOfForeignTaxAndResearchCredits
0
CY2014 lnth Income Tax Reconciliation Tax Credits Foreign Adjustment
IncomeTaxReconciliationTaxCreditsForeignAdjustment
-614000
CY2014 lnth Income Tax Reconciliation Tax Credits Research Adjustment
IncomeTaxReconciliationTaxCreditsResearchAdjustment
1204000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2431000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
3100000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
265000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2869000
CY2015 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
-37000
CY2015 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
7900000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2015 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
747000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2002000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8857000
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
99000
CY2015 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
19651000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1125000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
218000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43894000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
97000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1600000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-753000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18904000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15101000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
157939000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2386000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1752000
CY2015 us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
9752000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
99000
CY2015 us-gaap Revenues
Revenues
293461000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
187000
CY2015 us-gaap Interest Paid
InterestPaid
40788000
CY2015 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
0
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-782000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-5000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3986000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2015 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-8000000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4122000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
21762000
CY2015 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
CY2015 us-gaap Gross Profit
GrossProfit
135522000
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
132000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-355000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2704000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
773000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11778000
CY2015 us-gaap Interest Expense
InterestExpense
38715000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-13151000
CY2015 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6304000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
1359000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15528000
CY2015 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
CY2015 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2670000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-9108000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
749000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1680000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14746000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2609000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
42530000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
638000
CY2015 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-230000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
999000
CY2015 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
13151000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
46000
CY2015 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
1191000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
174000
CY2015 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-355000
CY2015 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
363000
CY2015 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
32000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
97000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2704000
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
2523000
CY2015 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
2500000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11778000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2968000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1894000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
478000
CY2015 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-38715000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
73539000
CY2015 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
7300000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24439845 shares
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
694000
CY2015 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
17400000
CY2016 us-gaap Advertising Expense
AdvertisingExpense
3600000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-91000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1549000
CY2016 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
576000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y6M
CY2015 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
400000000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24439845 shares
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14358000
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
360438000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6925000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.44
CY2015 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
236000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34740000
CY2015 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
0
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2002000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1900000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2015 lnth Tax Indemnification Income Loss
TaxIndemnificationIncomeLoss
1655000
CY2015 lnth Deferred Tax Assets Valuation Allowance Foreign Currency Translation Adjustments
DeferredTaxAssetsValuationAllowanceForeignCurrencyTranslationAdjustments
590000
CY2015 lnth Operating Expenses Before Gain Loss On Sale Of Assets
OperatingExpensesBeforeGainLossOnSaleOfAssets
92992000
CY2015 lnth Other Comprehensive Income Loss Reclassification Adjustment Due To Sale Of Group Of Assets Liabilities Not Qualifying As Discontinued Operations
OtherComprehensiveIncomeLossReclassificationAdjustmentDueToSaleOfGroupOfAssetsLiabilitiesNotQualifyingAsDiscontinuedOperations
0
CY2015 lnth Income Tax Reconciliation Write Off Of Foreign Tax And Research Credits
IncomeTaxReconciliationWriteOffOfForeignTaxAndResearchCredits
0
CY2015 lnth Income Tax Reconciliation Tax Credits Foreign Adjustment
IncomeTaxReconciliationTaxCreditsForeignAdjustment
-306000
CY2015 lnth Income Tax Reconciliation Tax Credits Research Adjustment
IncomeTaxReconciliationTaxCreditsResearchAdjustment
120000
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1603000
CY2016 dei Entity Registrant Name
EntityRegistrantName
LANTHEUS HOLDINGS, INC.
CY2016 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
600000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001521036
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1896000
CY2016 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
933000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2524000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22582000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-17000
CY2016 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
18263000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4990000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-49000
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38832000
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
602000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Concentration of Risks and Limited Suppliers</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to large national distributors, which in turn, may resell the Company&#x2019;s products.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The following table sets forth customers that contributed revenues of 10% or more during any of the years ended December&#xA0;31, 2016, 2015 and 2014 and/or represented 10% or more of the total net accounts receivable balance at either December&#xA0;31, 2016 or 2015:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="29%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Accounts<br /> Receivable</b><br /> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Revenues</b><br /> <b>Year Ended</b><br /> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>&#xA0;&#xA0;2016&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>&#xA0;&#xA0;2015&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>&#xA0;&#xA0;2016&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>&#xA0;&#xA0;2015&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>&#xA0;&#xA0;2014&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Company A</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">***</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">***</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Company B</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;13.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;12.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;11.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;11.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;11.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 142px; WHITE-SPACE: normal; WORD-SPACING: 0px; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; LINE-HEIGHT: 8pt; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">***</td> <td valign="top" align="left">Amount represented less than 10% for the reporting period</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company&#x2019;s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company&#x2019;s materials from these sources could have a material adverse effect on the Company&#x2019;s business, financial position and results of operations.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Historically, an important supplier of Moly and Xenon was Nordion, which relied on the NRU reactor in Chalk River, Ontario. From November 2016 the NRU reactor transitioned from providing regular supply of medical isotopes to providing only an emergency&#xA0;<font style="WHITE-SPACE: nowrap">back-up</font>&#xA0;of HEU based Moly through March 2018. For Moly and Xenon, the Company had supply agreements with Nordion that expired on October&#xA0;31, 2016. The Company currently has Moly supply agreements with NTP Radioisotopes (&#x201C;NTP&#x201D;), ANSTO and Institute for Radioelements (&#x201C;IRE&#x201D;), each with an expiration date of December&#xA0;31, 2017 and a Xenon supply agreement with IRE which runs through June&#xA0;30, 2019, subject to extensions. The Company currently relies on IRE as the sole supplier of bulk-unprocessed Xenon which the Company processes and finishes for its customers.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company currently relies on JHS as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company recently completed its technology transfer activities at JHS and received FDA approval for its Cardiolite product supply. In the meantime, the Company has no other currently active supplier of DEFINITY, Neurolite and Cardiolite.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Based on current projections, the Company believes that it will have sufficient supply of DEFINITY, Neurolite, Cardiolite and evacuation vials from JHS to meet expected demand.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The following table sets forth revenues for each of the Company&#x2019;s products representing 10% or more of revenues:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> DEFINITY</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;43.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;38.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"> &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;31.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> TechneLite</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Xenon</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">***</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 2pt; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 142px; WHITE-SPACE: normal; WORD-SPACING: 0px; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; LINE-HEIGHT: 8pt; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">***</td> <td valign="top" align="left">Amount represented less than 10% for the reporting period</td> </tr> </table> </div>
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1600000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-124000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17330000
CY2016 us-gaap Depreciation
Depreciation
800000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27800000
CY2016 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5100000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
164073000
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1689000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-853000
CY2016 us-gaap Asset Retirement Obligation Liabilities Settled
AssetRetirementObligationLiabilitiesSettled
284000
CY2016 us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
0
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3M18D
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-17000
CY2016 us-gaap Revenues
Revenues
301853000
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-112000
CY2016 us-gaap Interest Paid
InterestPaid
24441000
CY2016 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
74000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-570000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
9000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2016 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
220000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1342000
CY2016 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
6385000
CY2016 us-gaap Gross Profit
GrossProfit
137780000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
9903000
CY2016 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
155000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1038000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-13292000
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
53000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
28294000
CY2016 us-gaap Interest Expense
InterestExpense
26618000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3281000
CY2016 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
11000
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
1342000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1059000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2016 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10605000
CY2016 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
1479000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
23736000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
4558000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-383000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5700000
CY2016 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Reclassifications</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain reclassifications have been made to conform the prior year consolidated financial statements and notes to the current year presentation. These reclassifications include:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">During the first quarter of 2016, the Company early adopted ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-17,</font> Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes on a retrospective basis. This standard requires all deferred taxes and liabilities, and any related valuation allowances, to be classified as <font style="WHITE-SPACE: nowrap">non-current</font> on the balance sheet. The adoption of this standard resulted in the reclassification of $0.1&#xA0;million of current deferred tax assets to noncurrent deferred tax assets and $0.2&#xA0;million of current deferred tax liabilities to noncurrent deferred tax liabilities on the consolidated balance sheet at December&#xA0;31, 2015.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Reclassification of $9.1&#xA0;million of computer software, net to property, plant&#xA0;&amp; equipment, net in the consolidated balance sheet at December&#xA0;31, 2015.</td> </tr> </table> </div>
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26762000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3626000
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
56588000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
565000
CY2016 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
200000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-30217000
CY2016 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7398000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-242000
CY2016 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-2751000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
265000
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
603000
CY2016 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
82000
CY2016 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18000
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
602000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-13292000
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1529000
CY2016 us-gaap Income Tax Examination Interest Expense
IncomeTaxExaminationInterestExpense
2000000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
28294000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1532000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Description of Business</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Holdings, a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (&#x201C;LMI&#x201D;), also a Delaware corporation.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and other products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company&#x2019;s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The Company sells its products globally and has operations in the U.S., Puerto Rico and Canada and third-party distribution relationships in Europe, Canada, Australia, Asia Pacific and Latin America.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company has a portfolio of nine commercial products, which are diversified across a range of imaging modalities. The Company&#x2019;s imaging agents include an ultrasound contrast agent and medical radiopharmaceuticals (including technetium generators), including the following:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the U.S., is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Xenon Xe 133 Gas (&#x201C;Xenon&#x201D;) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography (&#x201C;SPECT&#x201D;) technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with SPECT technology in myocardial perfusion imaging (&#x201C;MPI&#x201D;), procedures that assess blood flow distribution to the heart.</td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In the U.S., the Company sells DEFINITY through its direct sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company&#x2019;s radiopharmaceutical products are primarily distributed through third-party commercial radiopharmacies.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s International operations consist of sales directly to end users through its wholly-owned radiopharmacy in Puerto Rico and sales through the Company&#x2019;s distributors in Canada, Europe, Australia, Asia Pacific and Latin America.</p> </div>
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
49642000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1129000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
433000
CY2016 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-26618000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50900000
CY2016 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1146000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40976 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company&#x2019;s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> </div>
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2080000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32655958 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M18D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2016 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
0
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M12D
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
593000
CY2016 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
13600000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2016 us-gaap Revenue Recognition Sales Returns
RevenueRecognitionSalesReturns
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Product Returns</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company provides a reserve for its estimate of sales recorded for which the related products are expected to be returned. The Company does not typically accept product returns unless an over shipment or <font style="WHITE-SPACE: nowrap">non-conforming</font> shipment was provided to the customer, or if the product was defective. The Company adjusts its estimate of product returns if it becomes aware of other factors that it believes could significantly impact its expected returns, including product recalls. These factors include its estimate of actual and historical return rates for <font style="WHITE-SPACE: nowrap">non-conforming</font> product and open return requests. Historically, the Company&#x2019;s estimates of returns have approximated actual returns.</p> </div>
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
27005 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.62
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48820000
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32043904 shares
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
231000
CY2016 dei Trading Symbol
TradingSymbol
LNTH
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
416000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12203000
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
231000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2006000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2016 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
36542000
CY2016 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
0
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2524000
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
78729000
CY2016 us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Rebates and Allowances</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Estimates for rebates and allowances represent the Company&#x2019;s estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for certain products, administration fees of group purchasing organizations and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third party&#x2019;s buying patterns and the resulting applicable contractual rebate or commission rate(s) to be earned over a contractual period.</p> </div>
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
15.66
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y3M18D
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 Segment
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2016 lnth Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod
75655 shares
CY2016 lnth Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice
16.26
CY2016 lnth Debt Retirement Cost
DebtRetirementCost
1896000
CY2016 lnth Financial Assurance In Form Of Surety Bond
FinancialAssuranceInFormOfSuretyBond
28200000
CY2016 lnth Income Tax Returns Period Subject To Examination
IncomeTaxReturnsPeriodSubjectToExamination
P3Y
CY2016 lnth Tax Indemnification Income Loss
TaxIndemnificationIncomeLoss
1055000
CY2016 lnth Incremental Common Shares Attributable To Restricted Stock Awards
IncrementalCommonSharesAttributableToRestrictedStockAwards
612054 shares
CY2016 lnth Period Over Which Cumulative Loss Was Incurred
PeriodOverWhichCumulativeLossWasIncurred
P3Y
CY2016 lnth Financial Assurance In Form Of Letter Of Credit
FinancialAssuranceInFormOfLetterOfCredit
8800000
CY2016 lnth Deferred Tax Assets Valuation Allowance Foreign Currency Translation Adjustments
DeferredTaxAssetsValuationAllowanceForeignCurrencyTranslationAdjustments
45000
CY2016 lnth Percentage Of Greatest Amount Of Letter Of Credit Drawn
PercentageOfGreatestAmountOfLetterOfCreditDrawn
1.05 pure
CY2016 lnth Operating Expenses Before Gain Loss On Sale Of Assets
OperatingExpensesBeforeGainLossOnSaleOfAssets
87577000
CY2016 lnth Vesting Of Restricted Stock Awards Value
VestingOfRestrictedStockAwardsValue
0
CY2016 lnth Other Comprehensive Income Loss Reclassification Adjustment Due To Sale Of Group Of Assets Liabilities Not Qualifying As Discontinued Operations
OtherComprehensiveIncomeLossReclassificationAdjustmentDueToSaleOfGroupOfAssetsLiabilitiesNotQualifyingAsDiscontinuedOperations
-435000
CY2016 lnth Income Tax Reconciliation Write Off Of Foreign Tax And Research Credits
IncomeTaxReconciliationWriteOffOfForeignTaxAndResearchCredits
7125000
CY2016 lnth Income Tax Reconciliation Tax Credits Foreign Adjustment
IncomeTaxReconciliationTaxCreditsForeignAdjustment
319000
CY2016 lnth Income Tax Reconciliation Tax Credits Research Adjustment
IncomeTaxReconciliationTaxCreditsResearchAdjustment
-90000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
74823000
CY2015Q1 us-gaap Gross Profit
GrossProfit
35769000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
375000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
73314000
CY2015Q2 us-gaap Gross Profit
GrossProfit
32667000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-24423000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
76474000
CY2016Q1 us-gaap Gross Profit
GrossProfit
33701000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
10323000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
77966000
CY2016Q2 us-gaap Gross Profit
GrossProfit
35751000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
7350000
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
74123000
CY2015Q3 us-gaap Gross Profit
GrossProfit
33705000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
5386000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
73063000
CY2016Q3 us-gaap Gross Profit
GrossProfit
33681000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
4220000
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
3916000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
74350000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2016Q4 us-gaap Gross Profit
GrossProfit
34647000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
4869000
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2015Q4 us-gaap Sales Revenue Net
SalesRevenueNet
71201000
CY2015Q4 us-gaap Gross Profit
GrossProfit
33381000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13

Files In Submission

Name View Source Status
0001193125-17-053986-index-headers.html Edgar Link pending
0001193125-17-053986-index.html Edgar Link pending
0001193125-17-053986.txt Edgar Link pending
0001193125-17-053986-xbrl.zip Edgar Link pending
d269039d10k.htm Edgar Link pending
d269039dex211.htm Edgar Link pending
d269039dex231.htm Edgar Link pending
d269039dex311.htm Edgar Link pending
d269039dex312.htm Edgar Link pending
d269039dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g269039g55h02.jpg Edgar Link pending
lnth-20161231.xml Edgar Link completed
lnth-20161231.xsd Edgar Link pending
lnth-20161231_cal.xml Edgar Link unprocessable
lnth-20161231_def.xml Edgar Link unprocessable
lnth-20161231_lab.xml Edgar Link unprocessable
lnth-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending